. >> mark schwartz is a biochemist who has been ceo of sell biotech companies. one of the issues is finding test patients who have not been given other drugs. >> if the spread of the disease, they may be willing to take patient that's have been pre treated with something else. >> the ceo of san francisco's company which uses artificial tension to the spread of no hopes the u.s. will look at other technologies. >> there needs to be effort on protective mechanisms. detection mechanisms, prediction mechanisms so we can say it will be worse in two weeks or this locale will be hit or i can talk to them within hours. >> the trial for rit. it is very possible country's agencies may have an early approval of the antiviral if it turns out to be effective with no side effects. abc7 news. >> all right. thank you. >>> we're asking how worried you are about the coronavirus and the range is pretty interesting. >> we can see somewhat worried is the main response. that's followed by extremely. only 12% of you say not at all. >> if you're looking for coronavirus information, we

. >> mark schwartz has served as ceo as several biotech companies. moderna has release a new vaccine to test on coronavirus. they have to be cautious about promising what their results will be. that's the risk they take. but they're also in business to make a profit. >> has the ability to quickly jump in with an existing molecule and an existing drug and potentially treat the pandemic. they will do that at some cost to them, because it's the right thing to do. >> the ceo of san francisco's kenzo, which uses artificial intelligence to track and predict the spread of flu hopes the u.s. will look at other technologies. >> there also needs to be effort on protective mechanisms, detection mechanisms, prediction mechanisms so that we can say hey, you know what? it is actually going to be bad, or it's going to be worse in two weeks, or this locale is going to get hit. or i can talk to a consumer within hours of their symptoms so that we can help get them better. >> according to gilead, its clinical trials are going to focus primarily on the drug's ability t

involvement was going back to at least december of '18 when he told me that one of his investigators, mark schwartz corruption in ukraine and certain people that were associated with it. giuliani asked m e to meet with that individual which i did and vetted a little bit. then lindsey back in january when we did the shokin interview, giuliani didn't trust the fbi or anybody he could take it to. the only person he said he trusts is lindsey graham, and that's who he would take it to. so it was understood that even at early stages, that lindsey graham was involved and aware of what was going on. now, what he did, that's what we have a trial for, and if the witnesses come out, you know, we would hear more and see if he took any action on certain things that i could testify and certain dates that giuliani told me. >> and in your new letter you say you would have testified to a conversation that you say you heard between giuliani and rick perry, who was then running the energy department and, quote, you said a quid pro quo was conveyed by mr. perry to zelensky. what can you tell us about that? >> absolute